Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B1208afd1a77436f1b7c806a50f0746b9> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B1208afd1a77436f1b7c806a50f0746b9 NCIT_P378 "NCI" @default.
- B1208afd1a77436f1b7c806a50f0746b9 type Axiom @default.
- B1208afd1a77436f1b7c806a50f0746b9 annotatedProperty IAO_0000115 @default.
- B1208afd1a77436f1b7c806a50f0746b9 annotatedSource NCIT_C187375 @default.
- B1208afd1a77436f1b7c806a50f0746b9 annotatedTarget "An orally bioavailable type II protein kinase inhibitor of multiple kinases, including c-Met (hepatocyte growth factor receptor; HGFR), FMS-like tyrosine kinase-3 (FLT3; CD135; fetal liver kinase-2; Flk2), tropomyosin-related-kinase (tyrosine receptor kinase; TRK), and cyclin-dependent kinases 8 and 19 (CDK8/19), with potential antineoplastic and immunomodulating activities. Upon oral administration, c-Met/FLT3/TRK/CDK8/19 inhibitor TSN084 targets, binds to and inhibits the activity of various kinases, such as c-Met, FLT3, TRK and CDK8/19, and prevents activation of oncogenic signaling pathways mediated by these kinases, blocks selective transcription of various tumor-promoting genes, and inhibits proliferation of susceptible tumor cells that overexpress these kinases. These kinases are overexpressed or mutated in certain cancer cell types and play key roles in tumor cell proliferation, survival, invasion, treatment resistance and immune evasion." @default.